Skip to main content

Phospholipid-mediated signaling systems as novel targets for treatment of heart disease

Buy Article:

$50.00 plus tax (Refund Policy)

The phospholipases associated with the cardiac sarcolemmal (SL) membrane hydrolyze specific membrane phospholipids to generate important lipid signaling molecules, which are known to influence normal cardiac function. However, impairment of the phospholipases and their related signaling events may be contributory factors in altering cardiac function of the diseased myocardium. The identification of the changes in such signaling systems as well as understanding the contribution of phospholipid-signaling pathways to the pathophysiology of heart disease are rapidly emerging areas of research in this field. In this paper, I provide an overview of the role of phospholipid-mediated signal transduction processes in cardiac hypertrophy and congestive heart failure, diabetic cardiomyopathy, as well as in ischemia–reperfusion. From the cumulative evidence presented, it is suggested that phospholipid-mediated signal transduction processes could serve as novel targets for the treatment of the different types of heart disease.

Les phospholipases associées à la membrane sarcolemmique (SL) cardiaque hydrolysent des phospholipides membranaires spécifiques pour produire d’importantes molécules de signalisation lipidique qui sont connues pour influencer la fonction cardiaque normale. Toutefois, l’altération des phospholipases et des événements de signalisation qui leur sont associés pourraient être des facteurs contribuant à la modification de la fonction cardiaque du myocarde malade. L’identification des modifications dans ces systèmes de signalisation et la compréhension de la contribution des voies de signalisation des phospholipides à la pathophysiologie de la maladie cardiaque sont des domaines de recherche en pleine expansion. Dans le présent article, je donne un aperçu du rôle des processus de transduction des signaux véhiculés par les phospholipides dans l’hypertrophie cardiaque et l’insuffisance cardiaque congestive, la cardiomyopathie diabétique et l’ischémie–reperfusion. À la lumière des résultats présentés, il est proposé que les processus de transduction des signaux véhiculés par les phospholipides soient utilisés comme de nouvelles cibles pour le traitement des différents types de maladies cardiaques.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Document Type: Research Article

Publication date: 2007-01-01

More about this publication?
  • Published since 1929, this monthly journal reports current research in all aspects of physiology, nutrition, pharmacology, and toxicology, contributed by recognized experts and scientists. It publishes symposium reviews and award lectures and occasionally dedicates entire issues or portions of issues to subjects of special interest to its international readership.
  • Information for Authors
  • Submit a Paper
  • Subscribe to this Title
  • Terms & Conditions
  • Sample Issue
  • Reprints & Permissions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more